

Zhou Xiaohui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5446800/publications.pdf>

Version: 2024-02-01

33
papers

1,570
citations

566801

15
h-index

377514

34
g-index

35
all docs

35
docs citations

35
times ranked

2228
citing authors

#	ARTICLE	IF	CITATIONS
1	Chlorogenic acid (CGA): A pharmacological review and call for further research. <i>Biomedicine and Pharmacotherapy</i> , 2018, 97, 67-74.	2.5	899
2	Comprehensive overview of prostatitis. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 1064-1076.	2.5	103
3	Pharmacological values and therapeutic properties of black tea (<i>Camellia sinensis</i>): A comprehensive overview. <i>Biomedicine and Pharmacotherapy</i> , 2018, 100, 521-531.	2.5	86
4	Role of oxidative stress in pathology of chronic prostatitis/chronic pelvic pain syndrome and male infertility and antioxidants function in ameliorating oxidative stress. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 714-723.	2.5	65
5	TRPM8 channels: A review of distribution and clinical role. <i>European Journal of Pharmacology</i> , 2020, 882, 173312.	1.7	58
6	Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 160-172.	1.0	35
7	Phytotherapy and physical therapy in the management of chronic prostatitis/chronic pelvic pain syndrome. <i>International Urology and Nephrology</i> , 2019, 51, 1081-1088.	0.6	28
8	Experimental rodent models of chronic prostatitis and evaluation criteria. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1894-1901.	2.5	27
9	Cardio-supportive devices (VRD & DCC device) and patches for advanced heart failure: A review, summary of state of the art and future directions. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 41-54.	2.5	22
10	A novel mouse model of chronic prostatitis/chronic pelvic pain syndrome induced by immunization of special peptide fragment with aluminum hydroxide adjuvant. <i>Immunology Letters</i> , 2017, 187, 61-67.	1.1	21
11	A novel ventricular restraint device (ASD) repetitively deliver <i>Salvia miltiorrhiza</i> to epicardium have good curative effects in heart failure management. <i>Biomedicine and Pharmacotherapy</i> , 2017, 95, 701-710.	2.5	21
12	Efficacy of acupuncture in the treatment of chronic prostatitis-chronic pelvic pain syndrome: a review of the literature. <i>International Urology and Nephrology</i> , 2019, 51, 2093-2106.	0.6	21
13	Establishment of a rat model of chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) induced by immunization with a novel peptide T2. <i>Biomedicine and Pharmacotherapy</i> , 2017, 91, 687-692.	2.5	20
14	Suppression of TGF β on myocardial remodeling by regulating the NF- κ B pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1460-1468.	2.5	15
15	Novel Treatment of Experimental Autoimmune Prostatitis by Nanoparticle-Conjugated Autoantigen Peptide T2. <i>Inflammation</i> , 2019, 42, 1071-1081.	1.7	15
16	An Immunogenic Peptide, T2 Induces Interstitial Cystitis/Painful Bladder Syndrome: an Autoimmune Mouse Model for Interstitial Cystitis/Painful Bladder Syndrome. <i>Inflammation</i> , 2017, 40, 2033-2041.	1.7	14
17	The promising future of ventricular restraint therapy for the management of end-stage heart failure. <i>Biomedicine and Pharmacotherapy</i> , 2018, 99, 25-32.	2.5	13
18	Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	13

#	ARTICLE	IF	CITATIONS
19	Cardiac support device (ASD) delivers bone marrow stem cells repetitively to epicardium has promising curative effects in advanced heart failure. <i>Biomedical Microdevices</i> , 2018, 20, 40.	1.4	11
20	A nanoparticle-coupled T2 peptide induces immune tolerance and ameliorates chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in mice model. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 267-276.	1.0	11
21	The effectiveness of <i>Hedyotis diffusa</i> Willd extract in a mouse model of experimental autoimmune prostatitis. <i>Andrologia</i> , 2021, 53, e13913.	1.0	11
22	Morphological reseach on expression of inflammatory mediators in murine models of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by T2 antigen. <i>Andrologia</i> , 2019, 51, e13435.	1.0	9
23	Effect of Oral T2 Antigen on Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Mice Model. <i>Inflammation</i> , 2019, 42, 2086-2094.	1.7	8
24	Therapeutic advances in cardiac targeted drug delivery: from theory to practice. <i>Journal of Drug Targeting</i> , 2021, 29, 235-248.	2.1	8
25	Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy. <i>International Urology and Nephrology</i> , 2021, 53, 607-618.	0.6	7
26	Herbal nutraceutical treatment of chronic prostatitis-chronic pelvic pain syndrome: a literature review. <i>International Urology and Nephrology</i> , 2021, 53, 1515-1528.	0.6	6
27	Therapeutic effects of Qianlie Tongli decoction on chronic prostatitis/chronic pelvic pain syndrome induced by peptide T2 in mice. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1436-1444.	1.2	5
28	The impact of clinical pharmacy services in Nepal in the context of current health policy: a systematic review. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2020, 28, 245-255.	0.8	4
29	A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 153-162.	1.0	4
30	T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune Prostatitis. <i>Inflammation</i> , 2021, 44, 243-248.	1.7	3
31	Therapeutic approach for global myocardial injury using bone marrow-derived mesenchymal stem cells by cardiac support device in rats. <i>Biomedical Microdevices</i> , 2021, 23, 5.	1.4	3
32	Therapeutic interventions to urologic chronic pelvic pain syndrome and UPOINT system for clinical phenotyping: How far are we?. <i>Urologia</i> , 2022, 89, 315-328.	0.3	2
33	A cardiac troponin I study in a minimally invasive myocardial infarction canine model. <i>Journal of Applied Biomedicine</i> , 2019, 17, 39-39.	0.6	1